Title:
ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/061457
Kind Code:
A1
Abstract:
Disclosed in the present invention are an antibody-drug conjugate, a pharmaceutical composition comprising the antibody-drug conjugate, and an application of the antibody-drug conjugate and the pharmaceutical composition in preparation of drugs for treating and/or preventing diseases.
Inventors:
TANG WEIJIA (CN)
QI XUEKANG (CN)
ZHOU XIN (CN)
YAN HUI (CN)
LI SHUOXU (CN)
FAN JIANJUN (CN)
MAI SIQI (CN)
YU JIN-CHEN (CN)
LI SHENGFENG (CN)
QI XUEKANG (CN)
ZHOU XIN (CN)
YAN HUI (CN)
LI SHUOXU (CN)
FAN JIANJUN (CN)
MAI SIQI (CN)
YU JIN-CHEN (CN)
LI SHENGFENG (CN)
Application Number:
PCT/CN2022/125205
Publication Date:
April 20, 2023
Filing Date:
October 13, 2022
Export Citation:
Assignee:
BIO THERA SOLUTIONS LTD (CN)
International Classes:
A61K47/68; A61K31/437; A61K45/00; A61K47/54; A61K47/60; A61P29/00; A61P31/00; A61P35/00; A61P35/02; A61P35/04; A61P37/02; C07K16/28
Foreign References:
| CN115429893A | 2022-12-06 | |||
| CN112138171A | 2020-12-29 |
Other References:
AZAR IBRAHIM, ALKASSIS SAMER, FUKUI JAMI, ALSAWAH FARES, FEDAK KALUB, AL HALLAK MOHAMMED NAJEEB, SUKARI AMMAR, NAGASAKA MISAKO: "Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer", LUNG CANCER: TARGETS AND THERAPY, vol. Volume 12, 7 October 2021 (2021-10-07), pages 103 - 114, XP093057018, DOI: 10.2147/LCTT.S307324
Download PDF: